Hikma Pharmaceuticals US unit launches injectable cancer treatment

Writer, Stock Market Wire
Tuesday, January 29, 2019 - 13:07

Hikma Pharmaceuticals said its US unit had launched its cancer treatment Mitomycin for injection.

The treatment was not recommended as single-agent, primary therapy but had been shown to be useful in treating disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents.

It was also useful as palliative treatment when other modalities had failed.

'We are excited to add Mitomycin for injection to our oncology portfolio in the US, improving patients' access to this important medicine,' injectables president Riad Mechlaoui said.

'This demonstrates the successful execution of our strategy to expand our portfolio in key therapeutic areas.'

At 1:07pm: (LON:HIK) Hikma Pharmaceuticals PLC share price was +19.25p at 1529.75p


Related content

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its equal weight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 1800p (from 1950p).

Broker Forecasts...

Thu, 21/03/2019 - 10:00


Broker Forecast - Jefferies International issues a broker note on Hikma Pharmaceuticals PLC

Jefferies International today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 1960p (from 2000p).

Broker Forecasts data...

Tue, 19/03/2019 - 10:10


Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC

Citigroup today upgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to buy (from neutral).

Broker Forecasts data provided by www.sharesmagazine.co.uk...

Tue, 19/03/2019 - 10:00


Broker Forecast - HSBC issues a broker note on Hikma Pharmaceuticals PLC

HSBC today reaffirms its reduce investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and raised its price target to 1350p (from 1225p).

Broker Forecasts data provided...

Thu, 14/03/2019 - 12:10


Broker Forecast - JP Morgan Cazenove issues a broker note on Hikma Pharmaceuticals PLC

JP Morgan Cazenove today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price target to 1700p (from 1800p).

Broker Forecasts...

Thu, 14/03/2019 - 09:10